<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wiessing, L.</style></author><author><style face="normal" font="default" size="100%">Ferri, M.</style></author><author><style face="normal" font="default" size="100%">Belackova, V.</style></author><author><style face="normal" font="default" size="100%">Carrieri, P.</style></author><author><style face="normal" font="default" size="100%">Friedman, S. R.</style></author><author><style face="normal" font="default" size="100%">Folch, C.</style></author><author><style face="normal" font="default" size="100%">Dolan, K.</style></author><author><style face="normal" font="default" size="100%">Galvin, B.</style></author><author><style face="normal" font="default" size="100%">Vickerman, P.</style></author><author><style face="normal" font="default" size="100%">Lazarus, J. V.</style></author><author><style face="normal" font="default" size="100%">Mravcik, V.</style></author><author><style face="normal" font="default" size="100%">Kretzschmar, M.</style></author><author><style face="normal" font="default" size="100%">Sypsa, V</style></author><author><style face="normal" font="default" size="100%">Sarasa-Renedo, A.</style></author><author><style face="normal" font="default" size="100%">Uuskula, A.</style></author><author><style face="normal" font="default" size="100%">Paraskevis, D</style></author><author><style face="normal" font="default" size="100%">Mendao, L.</style></author><author><style face="normal" font="default" size="100%">Rossi, D.</style></author><author><style face="normal" font="default" size="100%">van Gelder, N.</style></author><author><style face="normal" font="default" size="100%">Mitcheson, L.</style></author><author><style face="normal" font="default" size="100%">Paoli, L.</style></author><author><style face="normal" font="default" size="100%">Gomez, C. D.</style></author><author><style face="normal" font="default" size="100%">Milhet, M.</style></author><author><style face="normal" font="default" size="100%">Dascalu, N.</style></author><author><style face="normal" font="default" size="100%">Knight, J.</style></author><author><style face="normal" font="default" size="100%">Hay, G.</style></author><author><style face="normal" font="default" size="100%">Kalamara, E.</style></author><author><style face="normal" font="default" size="100%">Simon, R.</style></author><author><style face="normal" font="default" size="100%">EUBEST working group</style></author><author><style face="normal" font="default" size="100%">Comiskey, C.</style></author><author><style face="normal" font="default" size="100%">Rossi, C</style></author><author><style face="normal" font="default" size="100%">Griffiths, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study</style></title><secondary-title><style face="normal" font="default" size="100%">Harm Reduct J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Harm reduction journal</style></alt-title><short-title><style face="normal" font="default" size="100%">Harm reduction journalHarm reduction journal</style></short-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Harm Reduction</style></keyword><keyword><style  face="normal" font="default" size="100%">*Quality of Health Care</style></keyword><keyword><style  face="normal" font="default" size="100%">Consensus</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Substance-Related Disorders/*therapy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Apr 22</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">19</style></pages><isbn><style face="normal" font="default" size="100%">1477-7517 (Electronic)1477-7517 (Linking)</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND AND AIMS: Despite advances in our knowledge of effective services for people who use drugs over the last decades globally, coverage remains poor in most countries, while quality is often unknown. This paper aims to discuss the historical development of successful epidemiological indicators and to present a framework for extending them with additional indicators of coverage and quality of harm reduction services, for monitoring and evaluation at international, national or subnational levels. The ultimate aim is to improve these services in order to reduce health and social problems among people who use drugs, such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection, crime and legal problems, overdose (death) and other morbidity and mortality. METHODS AND RESULTS: The framework was developed collaboratively using consensus methods involving nominal group meetings, review of existing quality standards, repeated email commenting rounds and qualitative analysis of opinions/experiences from a broad range of professionals/experts, including members of civil society and organisations representing people who use drugs. Twelve priority candidate indicators are proposed for opioid agonist therapy (OAT), needle and syringe programmes (NSP) and generic cross-cutting aspects of harm reduction (and potentially other drug) services. Under the specific OAT indicators, priority indicators included 'coverage', 'waiting list time', 'dosage' and 'availability in prisons'. For the specific NSP indicators, the priority indicators included 'coverage', 'number of needles/syringes distributed/collected', 'provision of other drug use paraphernalia' and 'availability in prisons'. Among the generic or cross-cutting indicators the priority indicators were 'infectious diseases counselling and care', 'take away naloxone', 'information on safe use/sex' and 'condoms'. We discuss conditions for the successful development of the suggested indicators and constraints (e.g. funding, ideology). We propose conducting a pilot study to test the feasibility and applicability of the proposed indicators before their scaling up and routine implementation, to evaluate their effectiveness in comparing service coverage and quality across countries. CONCLUSIONS: The establishment of an improved set of validated and internationally agreed upon best practice indicators for monitoring harm reduction service will provide a structural basis for public health and epidemiological studies and support evidence and human rights-based health policies, services and interventions.</style></abstract><accession-num><style face="normal" font="default" size="100%">28431584</style></accession-num><notes><style face="normal" font="default" size="100%">Wiessing, LucasFerri, MaricaBelackova, VendulaCarrieri, PatriziaFriedman, Samuel RFolch, CintaDolan, KateGalvin, BrianVickerman, PeterLazarus, Jeffrey VMravcik, ViktorKretzschmar, MirjamSypsa, VanaSarasa-Renedo, AnaUuskula, AnneliParaskevis, DimitriosMendao, LuisRossi, Dianavan Gelder, NadineMitcheson, LukePaoli, LetiziaGomez, Cristina DiazMilhet, MaitenaDascalu, NicoletaKnight, JonathanHay, GordonKalamara, EleniSimon, RolandComiskey, CatherineRossi, CarlaGriffiths, PaulengConsensus Development ConferenceResearch Support, Non-U.S. Gov'tResearch Support, N.I.H., ExtramuralEngland2017/04/23 06:00Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6.</style></notes><custom2><style face="normal" font="default" size="100%">5401609</style></custom2><auth-address><style face="normal" font="default" size="100%">European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praca Europa 1, Cais do Sodre, 1249-289, Lisbon, Portugal. Lucas.Wiessing@emcdda.europa.eu.European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Praca Europa 1, Cais do Sodre, 1249-289, Lisbon, Portugal.Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.National Institute for Mental Health, Prague, Czech Republic.Uniting Medically Supervised Injecting Centre, Sydney, Australia.Marseille Univ, INSERM, IRD, SESSTIM, Marseille, France.ORS PACA, Marseille, France.Institute of Infectious Disease Research, National Development and Research Institutes, New York, USA.Centre d'Estudis Epidemiologics sobre les Infeccions de Transmissio Sexual i Sida de Catalunya (CEEISCAT), Agencia de Salut Publica de Catalunya (ASPC), Barcelona, Spain.Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.Program of International Research and Training, National Drug and Alcohol Research Centre, The University of New South Wales (UNSW), Sydney, Australia.Health Research Board, Dublin, Ireland.School of Social and Community Medicine, University of Bristol, Bristol, UK.CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.Barcelona Institute of Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.National Monitoring Centre for Drugs and Addiction, Prague, Czech Republic.Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.Spanish Field Epidemiology Training Program (PEAC), National Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain.Department of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.Group of Activists on Treatments (GAT), Lisbon, Portugal.Intercambios Civil Association and University of Buenos Aires, Buenos Aires, Argentina.Alcohol, Drug, and Tobacco Division, Health and Wellbeing Directorate, Public Health England, London, UK.Leuven Institute of Criminology (LINC), Faculty of Law, University of Leuven, Leuven, Belgium.Centre for Global Governance Studies (GSS), Leuven, Belgium.French Monitoring Centre for Drugs and Drug Addiction (OFDT), Saint-Denis, France.The Romanian Association Against AIDS (ARAS), Bucharest, Romania.Department of Health, Wellington House, London, UK.Public Health Institute, Faculty of Education, Health and Community, Liverpool John Moores University, Liverpool, UK.Trinity College Dublin, The University of Dublin, Dublin, Ireland.Centro Studi Statistici e Sociali CE3S, Rome, Italy.</style></auth-address></record></records></xml>